High Volume Screening Procedures for Hypobetalipoproteinemic Activity in Rats

  • Paul E. Schurr
  • John R. Schultz
  • Charles E. Day
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 67)


We describe high volume screening tests for hypobetalipoproteinemic agents in which compounds are administered orally to cholesterol-cholic acid fed (hypercholesterolemic) or normally fed weanling rats for 4 days. In these tests total serum cholesterol levels and heparin precipitating lipoproteins (HPL) are determined by automated analyses interfaced with a computer which eliminates all manual data reduction and provides necessary reports. The hypercholesterolemic rat test detects compounds which specifically reduce HPL (beta and pre beta lipoproteins) causing a decrease in the HPL:cholesterol ratio. Such activity is called hypobetalipoproteinemia. This activity is exhibited by bicyclo(2.2.2)-octyloxyaniline (U-26328) but not by any of the familiar hypocholesterolemic agents including clofibrate, lifibrate, nicotinic acid, probucol, triparanol, lentysine, D-thyroxine or the estrogens estrone and diethylstilbestrol.


Nicotinic Acid Lower Density Lipoprotein Cholic Acid Screening Procedure Total Serum Cholesterol Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Levy, R.S. and C.E. Day. 1970. Low density lipoprotein structure and its relation to atherogenesis. In: Atherosclerosis: Proceedings of the Second International Symposium. Ed. by R.V. Jones, Springer-Verlag, New York, pp. 186–189.Google Scholar
  2. 2.
    Day, C.E. and R.S. Levy. 1975. Control of the precipitation reaction between low density lipoproteins and polyions. Artery 1:150–164.Google Scholar
  3. 3.
    Alexander, C. and C.E. Day. 1973. Distribution of serum lipoproteins of selected vertebrates. Comp. Biochem. Physiol. 46B:295–312.Google Scholar
  4. 4.
    Day, C.E., B. Barker, and W.W. Stafford. 1974. Composition of very low density lipoproteins from cholesterol fed animals. Comp. Biochem. Physiol. 49B:501–505.Google Scholar
  5. 5.
    Day, C.E., P.E. Schurr, W.E. Heyd, and D. Lednicer. 1976. Biological activity of a hypobetalipoproteinemic agent. In: Atherosclerosis Drug Discovery Ed. by C.E. Day, Plenum Press, New York, pp. 231–249.Google Scholar
  6. 6.
    Block, W.D., K.J. Jarrett Jr., and J.B. Levine. 1965. Use of a single color reagent to improve the automated determination of serum total cholesterol. In: Automation in Analytical Chemistry, Ed. by L.T. Skeggs Jr., Mediad Inc., New York, pp. 345–347.Google Scholar
  7. 7.
    Lopez. A., R. Vial, L. Gremillion, and L. Bell. 1971. Automated simultaneous turbidimetric determination of cholesterol in β-and pre-β-lipoproteins. Clin. Chem. 17:994–997.PubMedGoogle Scholar
  8. 8.
    Snedecor, G.W., and W.G. Cochran. 1969. Statistical Methods. Iowa State University Press, Ames, Iowa, pp. 258–296.Google Scholar
  9. 9.
    Pearson, E.S. and H.O. Hartley. 1951. Charts of the power function for analysis of variance tests, derived from the non-central F-distribution. Biometrika 38:112–130.PubMedGoogle Scholar
  10. 10.
    Barnhart, J.W., V.A. Sefranka, and D.D. McIntosh. 1970. Hypocholesterolemic effect of 4,4′-(isopropylidenedithio)-bis (2,6-di-t-butylphenol) (Probucol). Am. J. Clin. Med. 23:1229–1233.Google Scholar
  11. 11.
    Blohm, T.R. and R.D. MacKenzie. 1959. Specific inhibition of cholesterol biosynthesis by a synthetic compound (MER-29). Arch. Biochem. Biophys. 85:245–249.PubMedCrossRefGoogle Scholar
  12. 12.
    Thorp, J.M. 1963. An experimental approach to the problem of disordered lipid metabolism. J. Atheroscler. Res. 3:351–360.PubMedCrossRefGoogle Scholar
  13. 13.
    Timms, A.R., L.A. Kelly, R.S. Ho, and J.H. Tropold. 1969. Laboratory studies of 1-methyl-4-piperidyl bis (p-chlorophenoxy) acetate (SaH 42-348) — a new hypolipidemic agent. Biochem. Pharmacol. 18:1861–1871.PubMedCrossRefGoogle Scholar
  14. 14.
    Levy, R.I., J. Morganroth, and B.M. Rifkind. 1974. Treatment of hyperlipidemia. N. Engl. J. Med. 290:1295–1301.PubMedCrossRefGoogle Scholar
  15. 15.
    Takashima, K., K. Izumi, and H. Iwai. 1973. The hypocholesterolemic action of eritadenine in the rat. Atherosclerosis 17: 491–502.PubMedCrossRefGoogle Scholar
  16. 16.
    Cohen, B.M. 1970. Sodium dextrothyroxine. Clin. Med. 77:25–32.Google Scholar
  17. 17.
    Merola, A.J. and A. Arnold. 1964. Estrone inhibition of cholesterol biosynthesis at the mevalonic acid stage. Science 144:301–302.PubMedCrossRefGoogle Scholar
  18. 18.
    Robinson, R.W., N. Higano, and W.D. Cohen. 1963. Long-term effects of high dosage estrogen therapy in men with coronary heart disease. J. Chron. Dis. 16:155–161.PubMedCrossRefGoogle Scholar
  19. 19.
    Day, C.E., P.E. Schurr, D.E. Emmert, R.E. Ten Brink, and D. Lednicer. 1975. Hypobetalipoproteinemic agents. I. Bicyclo (2.2.2.)octyloxyaniline and its derivatives. J. Med. Chem. 18: 1065–1070.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1976

Authors and Affiliations

  • Paul E. Schurr
    • 1
  • John R. Schultz
    • 1
  • Charles E. Day
    • 1
  1. 1.The Upjohn CompanyKalamazooUSA

Personalised recommendations